Objective To investigate the effect of levocanidine combined with high-flux hemodialysis（HFHD） on routine blood and inflammatory factor levels in patients with uremia. Methods A total of 162 patients with uremia admitted to a hospital in Zhengzhou from January 2018 to January 2021 were selected and assigned to a combination group and a single group using the random number table method

with 81 cases in each group. Patients in the single group received HFHD

and patients in the combined group levocanidine in combination with HFHD. The clinical efficacy

changes in renal function

routine blood [hemoglobin（Hb）

hematocrit（HCT）

red blood cell count（RBC）]

inflammatory factors [interleukin-1（IL-1）

C-reactive protein（CRP）]

and immune cytokines（CD3

+

CD4

+

） before and after treatment were compared between the 2 groups.Results The total effective rate for patients in the combined group was 86.42%

which was higher than that of the single group（69.14%）

and the difference was statistically significant（χ~2=7.000

P=0.008）. Hb

RBC

HCT and serum CD3

+

and CD4

+

levels in the two groups after treatment were higher than those before treatment

with the combined group higher than the single group

and the differences were statistically significant（P

<

0.05）. The levels of urea nitrogen

creatinine

IL-1 and CRP in the 2 groups were lower than those before treatment

with the combined group lower than the single group

and the differences were statistically significant（P

<

0.05）. Conclusion Levocarnitine in combination with high-flux hemodialysis is effective in patients with uremia

which can reduce inflammatory response

strengthen immunity

and improve routine blood and renal function indexes.